Eisai R&d Management Co., Ltd.

Kunitoshi Takeda

Yuichi Suzuki

Yoichi Kita

Mamoru Takaishi

Takafumi Motoki

Tasuku Ishida

Toshihiko Kaneko

Kogyoku Shin

Afzal Khan

Noboru Yamamoto

Paschalis Dimopoulos

Yoshinori Takahashi

Nobuaki Sato

Yoshihiko Norimine

Taro Terauchi

Yuki Ishihara

Kodo Shikata

Minako Hashizume

Akira Inomata

Toru Watanabe

Hisashi Shibata

Makoto Kotake

Shinsuke Hirota

Yu Yoshida

Yoshiaki Ohashi

Yoshihisa Kobayashi

Koji Hagiwara

Takashi Fukuyama

Tomoyuki Shibuguchi

Yasuaki Kamada

Toshiki Kurokawa

Hironori Fukumoto

Compounds represented by formulae (I) to (XXII) or pharmaceutically acceptable salts thereof: 

Pyranodipyridine compound

A compound represented by formula (I), or a pharmaceutically acceptable salt thereof: wherein Rrepresents a group represented by the formula: a group represented by the formula: or a group represented by the formula: and Rrepresents a 3-methyltetrahydro-2H-pyran-4-yl group or 4-methoxycyclohexyl group.

Pyridinylpyrazoloquinoline compounds

A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a Caryl group or the like, L is &#x2014;NRCO&#x2014; or the like (wherein Ris a hydrogen atom or the like), Ring B is a Caryl group or the like, X is a Calkylene group or the like, Y is a single bond or the like, Z is a Calkylene group or the like, Rand Rare each independently a hydrogen atom or the like, and R, R, Rand Rare independently a hydrogen atom, a halogen atom or the like, has an A&#x3b2; production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A&#x3b2; and typified by Alzheimer-type dementia.

Fused aminodihydrothiazine derivatives

A compound and/or pharmacologically acceptable salt thereof represented by the formula (I) has PDE9 inhibitory action, so that the intracerebral cGMP concentration is anticipated to be elevated. The PDE9 inhibitory action and the increase in cGMP lead to the improvement of learning and memory behaviors, and the compound (I) has a potential use of a therapeutic agent for cognitive dysfunctions in Alzheimer's disease. wherein Ris a hydrogen atom; Ris an aromatic ring group, etc.; Ris a hydrogen atom, etc; Ris a hydrogen atom; Ris an oxepanyl group, etc.; Ris a hydrogen atom.

Pyrazoloquinoline derivatives

A compound represented by the formula (I) or pharmacologically acceptable salt thereof exhibits an excellent CRF receptor antagonism wherein X is a nitrogen atom or CH; Ris -A-A; Ais a single bond or a C1-6 alkylene group; Ais a hydrogen atom, a C1-6 alkyl group or a C3-6 cycloalkyl group, etc.; Ris -A-A; Ais a single bond or a C1-6 alkylene group; Ais a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, a non-aromatic heterocyclic group, or a heteroaryl group, etc.; Ris a C1-6 alkyl group, a C3-6 cycloalkyl group, a C1-6 alkoxy group, a C3-6 cycloalkoxy C1-6 alkyl group, di-C1-6 alkyl amino group, a halogen atom, a cyano group, a formyl group, or a carboxyl group, etc; Ris a hydrogen atom or a C1-6 alkoxy group; Ris a halogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group; Ris a hydrogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkylthio group, or a C1-6 alkyl sulfinyl group etc.; and Ris a C1-6 alkyl group, a C1-6 alkoxy group, or a C1-6 alkylthio group.

Pyrazolothiazole compound

A compound represented by the following formula (I), or salt thereof exhibits excellent CRF receptor antagonism, and sufficient pharmacological activity, safety and pharmacokinetic properties as a drug. 

[object Object]

A compound represented by the general formula: wherein Ring A is a Caryl group or the like, L is &#x2014;NRCO&#x2014; or the like (wherein Ris a hydrogen atom or the like), Ring B is a Caryl group or the like, X is a Calkylene group or the like, Y is a Calkylene group or the like, Z is an oxygen atom or the like, Rand Rare each independently a hydrogen atom or the like, and R, R, Rand Rare independently a hydrogen atom, a halogen atom or the like, or a pharmaceutically acceptable salt thereof, or a solvate thereof, has an A&#x3b2; production inhibitory effect or a BACE1 inhibitory effect and is useful as a therapeutic agent for a neurodegenerative disease caused by A&#x3b2; and typified by Alzheimer-type dementia.

Fused aminodihydrothiazine derivative

Growing community of inventors

Tsukuba, Japan

Kunitoshi Takeda